Dermojet delivery of bleomycin for the treatment of recalcitrant plantar warts.
BACKGROUND
Plantar warts may cause significant morbidity. Intralesional bleomycin is effective. When bleomycin is injected with a needle and syringe, it is difficult to prevent the bleomycin from infiltrating the dermis adjacent to the wart, producing unnecessary acute pain, persistent pain, and potential sloughing of normal adjacent skin. Efficacy of delivery by dermojet is not yet established.


OBJECTIVE
To assess the response of recalcitrant plantar warts to bleomycin delivered by dermojet.


METHODS
A total of 47 patients with 138 plantar warts present for more than 2 years and resistant to 10 cycles of cryosurgery, were recruited. Bleomycin (1 U/ml) was delivered intralesionally by dermojet at 5-week intervals for 25 weeks.


RESULTS
Out of 138, 124 (89.9%) plantar warts showed complete or partial clearance after one to five sets of bleomycin injections. The recurrence rate was 6/138 (4.4%), and 8/138 (5.8%) warts failed to clear. The reduction in mean surface area of the plantar warts after each set of bleomycin injections compared to baseline surface area was statistically significant. Local side effects were similar to other methods of delivery. No systemic side effects were reported.


CONCLUSIONS
This study assesses therapeutic efficacy of bleomycin delivered by dermojet in solely recalcitrant plantar warts. It provides preliminary evidence that this method of delivery may benefit a group of patients with particularly recalcitrant plantar warts and is safe and easy to use in routine dermatology practice.
Agius
Elaine
E
Department of Dermatology, University College London Hospitals, London, UK. elaineagius@doctors.org.uk
Mooney
Jean M
JM
Bezzina
Audrienne Cutajar
AC
Yu
Raymond C
RC
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage*; D005534:Foot Diseases / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional / Q000295:instrumentation; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D014860:Warts / Q000188:drug therapy* / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D001761:Bleomycin